Cybin Inc. CYBN CYBN, a clinical-stage biopharmaceutical company focused on developing next-generation psychedelic treatments for mental health disorders, announced Wednesday its financial results for the fiscal quarter and year ending March 31, 2024, alongside significant strides in psychedelic therapy development. Cybin reported a net loss of C$78 million ($57 million) for FY 2024, a noticeable increase from C$47 million the previous year.
Despite these losses, the company maintained a robust cash reserve of C$209 million, bolstered by a successful $150 million private placement.
Operational expenditures related to research, general, and administrative activities totaled C$65 million for the year, reflecting an aggressive expansion in Cybin's developmental initiatives. Cash flows from operating activities increased significantly to C$69 million, up from C$47 million, highlighting the escalated investment in their pioneering research.
2024 marked a pivotal year for Cybin, with the FDA granting Breakthrough Therapy Designation (BTD) to CYB003, their proprietary psilocybin analog for treating Major Depressive Disorder (MDD). This designation accelerates the development timeline, with Phase 3 trials set to commence in summer 2024. Preliminary results from CYB003's Phase 2 trials demonstrated significant reductions in MDD symptoms, promising a transformative impact on treatment paradigms.
Additionally, Cybin initiated a Phase 2 study of CYB004, aimed at treating Generalized Anxiety Disorder (GAD) with a deuterated DMT molecule. This study is expected to shed light on CYB004's efficacy and the duration of its therapeutic effects, with results anticipated by year-end.
Cybin has considerably strengthened its intellectual property portfolio, securing multiple patents across key markets, ensuring exclusivity until at least 2040. Moreover, the company expects the upcoming year to be transformative, with further clinical milestones expected as Cybin continues to innovate in the mental health space.
Cybin's CEO, Doug Drysdale, remains optimistic about the company’s trajectory, citing the robust financial backing and promising clinical data as key drivers for continued innovation and growth in the sector. "Cybin's momentum continues, and 2024 will be another year of regulatory engagement and acceleration for our lead clinical programs. We are grateful for the financial support to continue this important work and look forward to sharing future updates on our progress," stated Drysdale.
CYBN Price Action
CYBN's shares were trading 3.90% lower at $0.2537 per share at the time of this writing around 10:40 AM ET Wednesday.
Related News:
Cannabis rescheduling seems to be right around the corner. Want to understand what this means for the future of the industry? Hear directly for top executives, investors and policymakers at the 19th Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9. Get your tickets now before prices surge by following this link.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join the Benzinga Cannabis Market Spotlight in New Jersey on June 17th! Grow your business, raise money and capitalize on the booming NJ recreational market. Don’t miss this must-attend event in New Brunswick. Secure your tickets now. Very few spots are left. Use the code “JAVIER20” for 20% off!